Radiopharm Theranostics has initiated a Phase 1 clinical trial for RAD 204, targeting PD-L1-positive non-small cell lung cancer.

Conducted at multiple Australian sites, including Wollongong Hospital in New South Wales, Princess Alexandra Hospital in Queensland, and Hollywood Private Hospital in Western Australia, RAD 204 aims to assess safety and preliminary efficacy in patients with metastatic NSCLC.

Radiopharm's previous Phase 1 diagnostic study demonstrated positive results, supporting its potential as a new treatment option for advanced NSCLC.